Trial Profile

An Open-label, Non-randomized, Phase I Study to Evaluate the Effect of Copanlisib (a Single Intravenous Dose of 60 mg) on the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Metformin (MATE2-K Substrate) in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Copanlisib (Primary) ; Metformin (Primary)
Indications Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Pharmacokinetics
Sponsors Bayer

21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
22 Feb 2019 Status changed from active, no longer recruiting to completed.
05 Feb 2019 Planned End Date changed from 18 Jan 2019 to 11 Feb 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com